



Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Date Published: Wednesday, 25 Sep 2024

DETAILED NEWS

↪ PRESS RELEASE 1 Recruitment in NATiv3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.

↪ Baseline characteristics of patients randomized in the main cohort of NATiv3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.

↪ Blinded analyses of patients in NATiv3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.

↪ Last patient randomization is anticipated in the first half of 2025 following the end of screening planned for the end of the year as guided.

↪ Topline results are expected in the second half of 2026.

↪ Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.01 1 million of short-term deposits and €9.0 2 million of long-term deposits as of December 31, 2023.

↪ Inventiva is actively reviewing potential financing and discussing strategic options with its financial advisors and potential counterparties, including its major shareholders and potential new investors.

↪ On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of €20.1 million.

↪ Cash runway extended until mid-October 2024 3, following the issuance of the royalty certificates announced on July 18, 2024, and the implementation of cash preservation measures.

↪ Short-term deposits were included in the category "other current assets" in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available.

- ↪ The long-term deposit had a two year-term, were accessible prior to the expiration of the term with a notice period of 31 days and were considered as liquid by the Company.

This estimate is based on the Company's current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue.

- ↪ The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated.

- ↪ PRESS RELEASE 2 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided a corporate and a financial update for the six months ended June 30, 2024.

- ↪ “ We are actively engaged in discussions seeking additional financing with the goal of funding the Company through the anticipated Phase III topline results.

- ↪ We believe the recent €20.1 million royalty deal, subscribed by Samsara BioCapital and longstanding shareholders such as BVF Partners, NEA, Sofinnova, and Yiheng, is a powerful endorsement of our strategy.

- ↪ Their continued support underscores their strong confidence in lanifibranor and our vision for transforming patient care.

- ↪ We remain confident in the ongoing progress of our Phase III NATiv3 clinical trial.” stated Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva.

KEY HIGHLIGHTS

- ↪ - The NATiv3 clinical trial has enrolled over 85% of its targeted patient number, with a statistical powering of the study expected to be over 95% for both doses evaluated in the trial.
- ↪ - The characteristics of patients enrolled in the main cohort of NATiv3 remain consistent with those of patients from the completed Phase IIb, NATIVE, clinical trial.
- ↪ - Analyses indicate positive evolution of key biomarkers and suggest that weight gain plateaus and stabilizes starting at week 24 to 36 in the NATiv3 trial.
- ↪ - The last patient randomization is expected in the first half of 2025, with topline results anticipated in the second half of 2026.
- ↪ - Inventiva's cash and cash equivalents stood at €10.1 million as of June 30, 2024, compared to €26.9 million at the end of 2023, with €0.01 million in short-term deposits and €9.0 million in long-term deposits.
- ↪ - Inventiva is exploring financing and strategic options with its financial advisors, major shareholders, and potential new investors.
- ↪ - On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders for an amount of €20.1 million.

- ↪ - Inventiva's cash runway has been extended until mid-October 2024, following the issuance of the royalty certificates and the implementation of cash preservation measures.

INSIGHTS

↪ 1.

- ↪ The NATiv3 clinical trial is advancing with over 85% of the target patient number enrolled, and the study is expected to have a statistical power above 95% for both doses evaluated in the trial.

- ↪ The baseline characteristics of patients remain consistent with those from the completed Phase IIb, NATIVE, clinical trial.

↪ 2.

- ↪ Blinded analyses indicate a positive evolution of key biomarkers, comparable to the Phase IIb, NATIVE, study results.

- ↪ The weight gain of patients seems to stabilize between weeks 24 to 36.

↪ 3.

- ↪ The last patient recruitment for the trial is expected in the first half of 2025, with topline results projected to be available in the second half of 2026.

↪ 4.

- ↪ As of June 30, 2024, Inventiva has cash and cash equivalents of €10.1 million, a decrease from €26.9 million at the end of 2023.

- ↪ In addition, there were €0.01 million of short-term deposits and €9.0 million of long-term deposits as of December 31, 2023.

↪ 5.

- ↪ Inventiva is actively exploring financing options and discussing strategic moves with its financial advisors and potential partners, including major shareholders and prospective new investors.

- ↪ On July 18, 2024, Inventiva issued royalty certificates worth €20.1 million to Samsara BioCapital and existing shareholders.

- ↪ This action, coupled with cash preservation measures, has extended the company's cash runway until mid-October 2024.

↪ 6.

- ↪ Inventiva, a clinical-stage biopharmaceutical company, is focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs.

- ↪ The company is actively seeking additional financing to fund its operations through the anticipated Phase III topline results.

CONFERENCE/WEBINAR/SUMMIT

↻ No events found.